Symbol:
Kmt2a
Name:
lysine methyltransferase 2A
RGD ID:
1586165
Description:
Enables DNA-binding transcription factor binding activity. Involved in several processes, including cellular response to transforming growth factor beta stimulus; membrane depolarization; and response to potassium ion. Predicted to be located in cytosol and nucleoplasm. Predicted to be part of MLL1 complex. Used to study transient cerebral ischemia. Human ortholog(s) of this gene implicated in acute myeloid leukemia; cervical cancer; myelofibrosis; and non-Hodgkin lymphoma. Orthologous to human KMT2A (lysine methyltransferase 2A); PARTICIPATES IN DNA modification pathway; histone modification pathway; INTERACTS WITH 2,3,7,8-tetrachlorodibenzodioxine; 2,3,7,8-Tetrachlorodibenzofuran; 2,4-dinitrotoluene.
Type:
protein-coding
RefSeq Status:
VALIDATED
Previously known as:
histone-lysine N-methyltransferase 2A; histone-lysine N-methyltransferase MLL; lysine (K)-specific methyltransferase 2A; Mixed-lineage leukemia (also acute lymphocytic leukemia 1 or trithorax Drosophila gene); Mixed-lineage leukemia (also acute lymphocytic leukemia 1 or tritorax Drosophila gene); Mll; Mll1; Mll_mapped; myeloid/lymphoid or mixed-lineage leukemia; myeloid/lymphoid or mixed-lineage leukemia (mapped); myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); myeloid/lymphoid or mixed-lineage leukemia 1
RGD Orthologs
Alliance Orthologs
More Info
more info ...
More Info
Latest Assembly:
GRCr8 - GRCr8 Assembly
Position:
Rat Assembly Chr Position (strand) Source Genome Browsers JBrowse NCBI UCSC Ensembl GRCr8 8 54,013,547 - 54,089,219 (-) NCBI GRCr8 mRatBN7.2 8 45,116,763 - 45,193,320 (-) NCBI mRatBN7.2 mRatBN7.2 mRatBN7.2 Ensembl 8 45,118,814 - 45,193,181 (-) Ensembl mRatBN7.2 Ensembl Rnor_6.0 8 49,110,407 - 49,185,872 (-) NCBI Rnor6.0 Rnor_6.0 rn6 Rnor6.0 Rnor_6.0 Ensembl 8 49,114,990 - 49,158,971 (-) Ensembl Rnor6.0 rn6 Rnor6.0 Rnor_5.0 8 47,728,915 - 47,804,551 (-) NCBI Rnor5.0 Rnor_5.0 rn5 Rnor5.0 RGSC_v3.4 8 47,759,175 - 47,834,586 (-) NCBI RGSC3.4 RGSC_v3.4 rn4 RGSC3.4 Celera 8 44,701,780 - 44,782,476 (-) NCBI Celera Cytogenetic Map 8 q22 NCBI
JBrowse:
View Region in Genome Browser (JBrowse)
Model
Only show annotations with direct experimental evidence (0 objects hidden)
Kmt2a Rat (1->4)-beta-D-glucan multiple interactions ISO Kmt2a (Mus musculus) 6480464 [perfluorooctane sulfonic acid co-treated with Cellulose] results in decreased expression of KMT2A mRNA CTD PMID:36331819 Kmt2a Rat 17beta-estradiol decreases expression ISO KMT2A (Homo sapiens) 6480464 Estradiol results in decreased expression of KMT2A mRNA CTD PMID:19167446 Kmt2a Rat 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO Kmt2a (Mus musculus) 6480464 Tetrachlorodibenzodioxin affects the expression of KMT2A mRNA CTD PMID:18691609 Kmt2a Rat 2,3,7,8-tetrachlorodibenzodioxine decreases expression EXP 6480464 Tetrachlorodibenzodioxin results in decreased expression of KMT2A mRNA CTD PMID:33387578 Kmt2a Rat 2,3,7,8-tetrachlorodibenzodioxine increases expression EXP 6480464 Tetrachlorodibenzodioxin results in increased expression of KMT2A mRNA CTD PMID:34747641 Kmt2a Rat 2,3,7,8-Tetrachlorodibenzofuran decreases expression EXP 6480464 2 more ... CTD PMID:32109520 Kmt2a Rat 2,4-dinitrotoluene affects expression EXP 6480464 2 and 4-dinitrotoluene affects the expression of KMT2A mRNA CTD PMID:21346803 Kmt2a Rat 2,6-dinitrotoluene affects expression EXP 6480464 2 and 6-dinitrotoluene affects the expression of KMT2A mRNA CTD PMID:21346803 Kmt2a Rat 2-hydroxypropanoic acid increases expression ISO KMT2A (Homo sapiens) 6480464 Lactic Acid results in increased expression of KMT2A mRNA CTD PMID:30851411 Kmt2a Rat 4,4'-sulfonyldiphenol decreases methylation ISO Kmt2a (Mus musculus) 6480464 bisphenol S results in decreased methylation of KMT2A exon CTD PMID:33297965 Kmt2a Rat 4,4'-sulfonyldiphenol affects methylation ISO Kmt2a (Mus musculus) 6480464 bisphenol S affects the methylation of KMT2A gene CTD PMID:31683443 Kmt2a Rat 4-octylphenol increases expression ISO KMT2A (Homo sapiens) 6480464 4-octylphenol results in increased expression of KMT2A protein CTD PMID:20056579 Kmt2a Rat 6-propyl-2-thiouracil decreases expression EXP 6480464 Propylthiouracil results in decreased expression of KMT2A mRNA CTD PMID:30047161 Kmt2a Rat aflatoxin B1 increases expression ISO Kmt2a (Mus musculus) 6480464 Aflatoxin B1 results in increased expression of KMT2A mRNA CTD PMID:19770486 Kmt2a Rat aflatoxin B1 increases methylation ISO KMT2A (Homo sapiens) 6480464 Aflatoxin B1 results in increased methylation of KMT2A exon CTD PMID:30157460 Kmt2a Rat all-trans-retinoic acid decreases expression ISO KMT2A (Homo sapiens) 6480464 Tretinoin results in decreased expression of KMT2A mRNA CTD PMID:22906706 and PMID:33167477 Kmt2a Rat alpha-Zearalanol multiple interactions EXP 6480464 [Zeranol co-treated with perfluorooctanoic acid] results in decreased expression of KMT2A mRNA CTD PMID:35163327 Kmt2a Rat amitrole decreases expression EXP 6480464 Amitrole results in decreased expression of KMT2A mRNA CTD PMID:30047161 Kmt2a Rat amphetamine decreases expression EXP 6480464 Amphetamine results in decreased expression of KMT2A mRNA CTD PMID:30779732 Kmt2a Rat arsenite(3-) multiple interactions ISO KMT2A (Homo sapiens) 6480464 arsenite inhibits the reaction [G3BP1 protein binds to KMT2A mRNA] CTD PMID:32406909 Kmt2a Rat arsenous acid multiple interactions ISO KMT2A (Homo sapiens) 6480464 [Arsenic Trioxide co-treated with Bortezomib] results in decreased expression of KMT2A mRNA CTD PMID:25913414 Kmt2a Rat benzo[a]pyrene decreases expression ISO KMT2A (Homo sapiens) 6480464 Benzo(a)pyrene results in decreased expression of KMT2A mRNA CTD PMID:22316170 Kmt2a Rat benzo[a]pyrene increases methylation ISO Kmt2a (Mus musculus) 6480464 Benzo(a)pyrene results in increased methylation of KMT2A exon CTD PMID:27901495 Kmt2a Rat benzo[a]pyrene diol epoxide I increases expression ISO KMT2A (Homo sapiens) 6480464 7 more ... CTD PMID:26238291 Kmt2a Rat benzo[e]pyrene increases methylation ISO KMT2A (Homo sapiens) 6480464 benzo(e)pyrene results in increased methylation of KMT2A exon CTD PMID:30157460 Kmt2a Rat bis(2-ethylhexyl) phthalate decreases expression ISO Kmt2a (Mus musculus) 6480464 Diethylhexyl Phthalate results in decreased expression of KMT2A mRNA CTD PMID:33754040 Kmt2a Rat bisphenol A decreases expression ISO KMT2A (Homo sapiens) 6480464 bisphenol A results in decreased expression of KMT2A mRNA CTD PMID:22576693 Kmt2a Rat bisphenol A decreases expression ISO Kmt2a (Mus musculus) 6480464 bisphenol A results in decreased expression of KMT2A mRNA CTD PMID:32156529 Kmt2a Rat bisphenol A increases expression EXP 6480464 bisphenol A results in increased expression of KMT2A mRNA CTD PMID:33441873 Kmt2a Rat bisphenol A multiple interactions ISO Kmt2a (Mus musculus) 6480464 [bisphenol A co-treated with LIF protein] results in decreased expression of KMT2A mRNA CTD PMID:30951980 Kmt2a Rat bisphenol A affects methylation ISO Kmt2a (Mus musculus) 6480464 bisphenol A affects the methylation of KMT2A promoter CTD PMID:27334623 Kmt2a Rat bisphenol A affects expression EXP 6480464 bisphenol A affects the expression of KMT2A mRNA CTD PMID:30816183 and PMID:35192832 Kmt2a Rat bisphenol A increases methylation ISO KMT2A (Homo sapiens) 6480464 bisphenol A results in increased methylation of KMT2A gene CTD PMID:22576693 Kmt2a Rat bisphenol AF increases expression ISO KMT2A (Homo sapiens) 6480464 bisphenol AF results in increased expression of KMT2A mRNA CTD PMID:25912373 Kmt2a Rat bortezomib multiple interactions ISO KMT2A (Homo sapiens) 6480464 [arsenic trioxide co-treated with Bortezomib] results in decreased expression of KMT2A mRNA CTD PMID:25913414 Kmt2a Rat butanal decreases expression ISO KMT2A (Homo sapiens) 6480464 butyraldehyde results in decreased expression of KMT2A mRNA CTD PMID:26079696 Kmt2a Rat cadmium atom decreases expression ISO KMT2A (Homo sapiens) 6480464 Cadmium results in decreased expression of KMT2A mRNA CTD PMID:21120746 Kmt2a Rat cadmium atom multiple interactions ISO Kmt2a (Mus musculus) 6480464 [Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of KMT2A mRNA CTD PMID:37325564 Kmt2a Rat cadmium atom multiple interactions ISO KMT2A (Homo sapiens) 6480464 [Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of KMT2A mRNA CTD PMID:35301059 Kmt2a Rat cadmium dichloride decreases expression ISO KMT2A (Homo sapiens) 6480464 Cadmium Chloride results in decreased expression of KMT2A mRNA CTD PMID:38568856 Kmt2a Rat cadmium dichloride multiple interactions ISO Kmt2a (Mus musculus) 6480464 [Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of KMT2A mRNA CTD PMID:37325564 Kmt2a Rat cadmium dichloride multiple interactions ISO KMT2A (Homo sapiens) 6480464 [Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of KMT2A mRNA CTD PMID:35301059 Kmt2a Rat caffeine affects phosphorylation ISO KMT2A (Homo sapiens) 6480464 Caffeine affects the phosphorylation of KMT2A protein CTD PMID:35688186 Kmt2a Rat chlorpyrifos increases mutagenesis ISO KMT2A (Homo sapiens) 6480464 Chlorpyrifos results in increased mutagenesis of KMT2A gene CTD PMID:26198043 Kmt2a Rat cisplatin decreases expression ISO KMT2A (Homo sapiens) 6480464 Cisplatin results in decreased expression of KMT2A mRNA CTD PMID:27594783 Kmt2a Rat cisplatin affects response to substance ISO KMT2A (Homo sapiens) 6480464 KMT2A protein affects the susceptibility to Cisplatin CTD PMID:16217747 Kmt2a Rat cladribine increases response to substance ISO KMT2A (Homo sapiens) 6480464 KMT2A gene mutant form results in increased susceptibility to Cladribine CTD PMID:14712291 Kmt2a Rat clozapine increases expression ISO KMT2A (Homo sapiens) 6480464 Clozapine results in increased expression of KMT2A mRNA CTD PMID:17942719 Kmt2a Rat clozapine decreases expression ISO Kmt2a (Mus musculus) 6480464 Clozapine results in decreased expression of KMT2A mRNA CTD PMID:14647396 Kmt2a Rat clozapine increases expression ISO Kmt2a (Mus musculus) 6480464 Clozapine results in increased expression of KMT2A mRNA CTD PMID:17942719 Kmt2a Rat clozapine multiple interactions ISO Kmt2a (Mus musculus) 6480464 Clozapine promotes the reaction [KMT2A protein binds to GAD1 promoter] CTD PMID:17942719 Kmt2a Rat cobalt atom increases expression ISO KMT2A (Homo sapiens) 6480464 Cobalt results in increased expression of KMT2A mRNA CTD PMID:26378417 Kmt2a Rat cobalt dichloride increases expression ISO KMT2A (Homo sapiens) 6480464 cobaltous chloride results in increased expression of KMT2A mRNA CTD PMID:26378417 Kmt2a Rat copper(II) sulfate decreases expression ISO KMT2A (Homo sapiens) 6480464 Copper Sulfate results in decreased expression of KMT2A mRNA CTD PMID:19549813 Kmt2a Rat coumarin affects phosphorylation ISO KMT2A (Homo sapiens) 6480464 coumarin affects the phosphorylation of KMT2A protein CTD PMID:35688186 Kmt2a Rat crotonaldehyde decreases expression ISO KMT2A (Homo sapiens) 6480464 2-butenal results in decreased expression of KMT2A mRNA CTD PMID:20471460 Kmt2a Rat Cuprizon increases expression EXP 6480464 Cuprizone results in increased expression of KMT2A mRNA CTD PMID:26577399 Kmt2a Rat cytarabine increases response to substance ISO KMT2A (Homo sapiens) 6480464 KMT2A gene mutant form results in increased susceptibility to Cytarabine CTD PMID:14712291 Kmt2a Rat deoxynivalenol increases expression ISO KMT2A (Homo sapiens) 6480464 deoxynivalenol results in increased expression of KMT2A mRNA CTD PMID:19438726 Kmt2a Rat deoxynivalenol multiple interactions ISO KMT2A (Homo sapiens) 6480464 AG 1879 inhibits the reaction [deoxynivalenol results in increased expression of KMT2A mRNA] more ... CTD PMID:19438726 Kmt2a Rat diarsenic trioxide multiple interactions ISO KMT2A (Homo sapiens) 6480464 [Arsenic Trioxide co-treated with Bortezomib] results in decreased expression of KMT2A mRNA CTD PMID:25913414 Kmt2a Rat diazinon increases methylation ISO KMT2A (Homo sapiens) 6480464 Diazinon results in increased methylation of KMT2A gene CTD PMID:22964155 Kmt2a Rat dibutyl phthalate decreases expression EXP 6480464 Dibutyl Phthalate results in decreased expression of KMT2A mRNA CTD PMID:21266533 Kmt2a Rat dicrotophos increases expression ISO KMT2A (Homo sapiens) 6480464 dicrotophos results in increased expression of KMT2A mRNA CTD PMID:28302478 Kmt2a Rat diethylstilbestrol multiple interactions ISO KMT2A (Homo sapiens) 6480464 [Diethylstilbestrol promotes the reaction [KMT2A protein binds to HOTAIR promoter]] which results in increased expression of HOTAIR mRNA and Diethylstilbestrol promotes the reaction [KMT2A protein binds to HOTAIR promoter] CTD PMID:24533973 Kmt2a Rat dorsomorphin multiple interactions ISO KMT2A (Homo sapiens) 6480464 [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 Kmt2a Rat doxorubicin decreases response to substance ISO KMT2A (Homo sapiens) 6480464 KMT2A gene mutant form results in decreased susceptibility to Doxorubicin and KMT2A mRNA results in decreased susceptibility to Doxorubicin CTD PMID:14712291 and PMID:16322897 Kmt2a Rat endosulfan decreases expression EXP 6480464 Endosulfan results in decreased expression of KMT2A mRNA CTD PMID:29391264 Kmt2a Rat enzyme inhibitor multiple interactions ISO KMT2A (Homo sapiens) 6480464 [Enzyme Inhibitors results in decreased activity of OGA protein] which results in increased O-linked glycosylation of KMT2A protein CTD PMID:23301498 Kmt2a Rat ethanol affects splicing ISO Kmt2a (Mus musculus) 6480464 Ethanol affects the splicing of KMT2A mRNA CTD PMID:30319688 Kmt2a Rat ethanol decreases expression ISO KMT2A (Homo sapiens) 6480464 Ethanol results in decreased expression of KMT2A mRNA CTD PMID:35149083 Kmt2a Rat etoposide increases response to substance ISO KMT2A (Homo sapiens) 6480464 KMT2A gene mutant form results in increased susceptibility to Etoposide CTD PMID:14712291 Kmt2a Rat etoposide increases mutagenesis ISO KMT2A (Homo sapiens) 6480464 Etoposide results in increased mutagenesis of KMT2A gene CTD PMID:28624474 Kmt2a Rat etoposide increases cleavage ISO KMT2A (Homo sapiens) 6480464 Etoposide results in increased cleavage of KMT2A gene CTD PMID:24086652 Kmt2a Rat fenthion decreases expression ISO Kmt2a (Mus musculus) 6480464 Fenthion results in decreased expression of KMT2A mRNA CTD PMID:34813904 Kmt2a Rat formaldehyde increases expression ISO KMT2A (Homo sapiens) 6480464 Formaldehyde results in increased expression of KMT2A mRNA CTD PMID:23649840 Kmt2a Rat FR900359 affects phosphorylation ISO KMT2A (Homo sapiens) 6480464 FR900359 affects the phosphorylation of KMT2A protein CTD PMID:37730182 Kmt2a Rat geldanamycin increases expression ISO KMT2A (Homo sapiens) 6480464 geldanamycin results in increased expression of KMT2A mRNA CTD PMID:26705709 Kmt2a Rat genistein increases mutagenesis ISO KMT2A (Homo sapiens) 6480464 Genistein results in increased mutagenesis of KMT2A gene CTD PMID:17468513 Kmt2a Rat gentamycin increases expression EXP 6480464 Gentamicins results in increased expression of KMT2A mRNA CTD PMID:22061828 Kmt2a Rat glyphosate affects methylation EXP 6480464 Glyphosate affects the methylation of KMT2A gene CTD PMID:35440735 Kmt2a Rat haloperidol decreases expression ISO Kmt2a (Mus musculus) 6480464 Haloperidol results in decreased expression of KMT2A mRNA CTD PMID:14647396 Kmt2a Rat hydroquinone multiple interactions ISO Kmt2a (Mus musculus) 6480464 [KMT2A mutant form results in decreased susceptibility to hydroquinone] which results in increased expression of APP mRNA more ... CTD PMID:37245849 Kmt2a Rat hydroquinone decreases response to substance ISO Kmt2a (Mus musculus) 6480464 KMT2A mutant form results in decreased susceptibility to hydroquinone CTD PMID:37245849 Kmt2a Rat kaempferol increases mutagenesis ISO KMT2A (Homo sapiens) 6480464 kaempferol results in increased mutagenesis of KMT2A gene CTD PMID:17468513 Kmt2a Rat malathion increases mutagenesis ISO KMT2A (Homo sapiens) 6480464 Malathion results in increased mutagenesis of KMT2A gene CTD PMID:28624474 Kmt2a Rat malathion increases expression ISO KMT2A (Homo sapiens) 6480464 Malathion results in increased expression of KMT2A mRNA mutant form CTD PMID:28624474 Kmt2a Rat methapyrilene increases methylation ISO KMT2A (Homo sapiens) 6480464 Methapyrilene results in increased methylation of KMT2A exon CTD PMID:30157460 Kmt2a Rat methidathion decreases expression ISO Kmt2a (Mus musculus) 6480464 methidathion results in decreased expression of KMT2A mRNA CTD PMID:34813904 Kmt2a Rat methimazole decreases expression EXP 6480464 Methimazole results in decreased expression of KMT2A mRNA CTD PMID:30047161 Kmt2a Rat methylmercury chloride increases expression ISO KMT2A (Homo sapiens) 6480464 methylmercuric chloride results in increased expression of KMT2A mRNA CTD PMID:23179753 and PMID:26272509 Kmt2a Rat molibresib decreases response to substance ISO Kmt2a (Mus musculus) 6480464 KMT2A protein results in decreased susceptibility to molibresib CTD PMID:26367796 Kmt2a Rat molibresib multiple interactions ISO Kmt2a (Mus musculus) 6480464 DKK1 protein inhibits the reaction [KMT2A protein results in decreased susceptibility to molibresib] and pyrvinium inhibits the reaction [KMT2A protein results in decreased susceptibility to molibresib] CTD PMID:26367796 Kmt2a Rat morphine multiple interactions EXP 6480464 Morphine promotes the reaction [KMT2A protein binds to BDNF promoter] CTD PMID:25643298 Kmt2a Rat morphine affects expression ISO Kmt2a (Mus musculus) 6480464 Morphine affects the expression of KMT2A mRNA CTD PMID:33891991 Kmt2a Rat N-acetyl-L-cysteine multiple interactions ISO KMT2A (Homo sapiens) 6480464 Acetylcysteine inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in increased expression of KMT2A protein] CTD PMID:31551408 Kmt2a Rat nickel dichloride affects expression EXP 6480464 nickel chloride affects the expression of KMT2A mRNA CTD PMID:22110744 Kmt2a Rat nickel dichloride increases expression ISO KMT2A (Homo sapiens) 6480464 nickel chloride results in increased expression of KMT2A mRNA CTD PMID:26378417 Kmt2a Rat Nonylphenol increases expression ISO KMT2A (Homo sapiens) 6480464 nonylphenol results in increased expression of KMT2A protein CTD PMID:20056579 Kmt2a Rat ozone multiple interactions ISO Kmt2a (Mus musculus) 6480464 [Air Pollutants results in increased abundance of Ozone] which results in decreased expression of KMT2A mRNA CTD PMID:34911549 Kmt2a Rat p-chloromercuribenzoic acid decreases expression ISO KMT2A (Homo sapiens) 6480464 p-Chloromercuribenzoic Acid results in decreased expression of KMT2A mRNA CTD PMID:26272509 Kmt2a Rat p-chloromercuribenzoic acid multiple interactions ISO KMT2A (Homo sapiens) 6480464 [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KMT2A mRNA CTD PMID:27188386 Kmt2a Rat paracetamol increases expression ISO KMT2A (Homo sapiens) 6480464 Acetaminophen results in increased expression of KMT2A mRNA CTD PMID:26690555 Kmt2a Rat paracetamol decreases expression EXP 6480464 Acetaminophen results in decreased expression of KMT2A mRNA CTD PMID:33387578 Kmt2a Rat perfluorooctane-1-sulfonic acid multiple interactions ISO Kmt2a (Mus musculus) 6480464 [perfluorooctane sulfonic acid co-treated with Cellulose] results in decreased expression of KMT2A mRNA CTD PMID:36331819 Kmt2a Rat perfluorooctanoic acid multiple interactions EXP 6480464 [Zeranol co-treated with perfluorooctanoic acid] results in decreased expression of KMT2A mRNA CTD PMID:35163327 Kmt2a Rat permethrin increases mutagenesis ISO KMT2A (Homo sapiens) 6480464 Permethrin results in increased mutagenesis of KMT2A gene CTD PMID:12937054 and PMID:28624474 Kmt2a Rat phenylmercury acetate decreases expression ISO KMT2A (Homo sapiens) 6480464 Phenylmercuric Acetate results in decreased expression of KMT2A mRNA CTD PMID:26272509 Kmt2a Rat phenylmercury acetate multiple interactions ISO KMT2A (Homo sapiens) 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KMT2A mRNA CTD PMID:27188386 Kmt2a Rat pirinixic acid decreases expression ISO Kmt2a (Mus musculus) 6480464 pirinixic acid results in decreased expression of KMT2A mRNA CTD PMID:17426115 Kmt2a Rat potassium chloride decreases expression EXP 6480464 Potassium Chloride results in decreased expression of KMT2A mRNA CTD PMID:20211609 Kmt2a Rat prednisolone decreases response to substance ISO KMT2A (Homo sapiens) 6480464 KMT2A gene mutant form results in decreased susceptibility to Prednisolone CTD PMID:14712291 Kmt2a Rat propiconazole decreases expression EXP 6480464 propiconazole results in decreased expression of KMT2A mRNA CTD PMID:30047161 Kmt2a Rat pyrvinium multiple interactions ISO Kmt2a (Mus musculus) 6480464 pyrvinium inhibits the reaction [KMT2A protein results in decreased susceptibility to molibresib] CTD PMID:26367796 Kmt2a Rat quercetin decreases expression ISO KMT2A (Homo sapiens) 6480464 Quercetin results in decreased expression of KMT2A mRNA CTD PMID:15309432 Kmt2a Rat quercetin increases mutagenesis ISO KMT2A (Homo sapiens) 6480464 Quercetin results in increased mutagenesis of KMT2A gene CTD PMID:17468513 Kmt2a Rat rac-lactic acid increases expression ISO KMT2A (Homo sapiens) 6480464 Lactic Acid results in increased expression of KMT2A mRNA CTD PMID:30851411 Kmt2a Rat SB 431542 multiple interactions ISO KMT2A (Homo sapiens) 6480464 [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 Kmt2a Rat silicon dioxide decreases expression ISO KMT2A (Homo sapiens) 6480464 Silicon Dioxide analog results in decreased expression of KMT2A mRNA CTD PMID:23806026 Kmt2a Rat sodium arsenate decreases expression ISO Kmt2a (Mus musculus) 6480464 sodium arsenate results in decreased expression of KMT2A protein CTD PMID:26193056 Kmt2a Rat sodium arsenate increases expression ISO Kmt2a (Mus musculus) 6480464 sodium arsenate results in increased expression of KMT2A mRNA and sodium arsenate results in increased expression of KMT2A protein CTD PMID:21795629 and PMID:26193056 Kmt2a Rat sodium arsenite increases expression ISO KMT2A (Homo sapiens) 6480464 sodium arsenite results in increased expression of KMT2A mRNA CTD PMID:38568856 Kmt2a Rat sulfadimethoxine decreases expression EXP 6480464 Sulfadimethoxine results in decreased expression of KMT2A mRNA CTD PMID:30047161 Kmt2a Rat testosterone enanthate affects expression ISO KMT2A (Homo sapiens) 6480464 testosterone enanthate affects the expression of KMT2A mRNA CTD PMID:17440010 Kmt2a Rat thimerosal decreases expression ISO KMT2A (Homo sapiens) 6480464 Thimerosal results in decreased expression of KMT2A mRNA CTD PMID:27188386 Kmt2a Rat thioacetamide increases expression EXP 6480464 Thioacetamide results in increased expression of KMT2A mRNA CTD PMID:34492290 Kmt2a Rat titanium dioxide increases expression ISO Kmt2a (Mus musculus) 6480464 titanium dioxide results in increased expression of KMT2A mRNA CTD PMID:29264374 Kmt2a Rat torcetrapib increases expression ISO KMT2A (Homo sapiens) 6480464 torcetrapib results in increased expression of KMT2A mRNA CTD PMID:23228038 Kmt2a Rat trichostatin A decreases expression ISO KMT2A (Homo sapiens) 6480464 trichostatin A results in decreased expression of KMT2A mRNA CTD PMID:24935251 and PMID:26272509 Kmt2a Rat trichostatin A multiple interactions ISO KMT2A (Homo sapiens) 6480464 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KMT2A mRNA CTD PMID:27188386 Kmt2a Rat triphenyl phosphate affects expression ISO KMT2A (Homo sapiens) 6480464 triphenyl phosphate affects the expression of KMT2A mRNA CTD PMID:37042841 Kmt2a Rat troglitazone decreases expression ISO Kmt2a (Mus musculus) 6480464 troglitazone results in decreased expression of KMT2A mRNA CTD PMID:28973697 Kmt2a Rat tungsten decreases expression ISO Kmt2a (Mus musculus) 6480464 Tungsten results in decreased expression of KMT2A mRNA CTD PMID:30912803 Kmt2a Rat valdecoxib increases expression EXP 6480464 valdecoxib results in increased expression of KMT2A mRNA CTD PMID:24136188 Kmt2a Rat valproic acid decreases expression ISO KMT2A (Homo sapiens) 6480464 Valproic Acid results in decreased expression of KMT2A mRNA CTD PMID:23179753 more ... Kmt2a Rat valproic acid decreases expression EXP 6480464 Valproic Acid results in decreased expression of KMT2A mRNA CTD PMID:29427782 Kmt2a Rat valproic acid multiple interactions ISO KMT2A (Homo sapiens) 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KMT2A mRNA CTD PMID:27188386 Kmt2a Rat vinclozolin affects expression EXP 6480464 vinclozolin affects the expression of KMT2A mRNA CTD PMID:19015723 Kmt2a Rat vorinostat decreases expression ISO KMT2A (Homo sapiens) 6480464 vorinostat results in decreased expression of KMT2A mRNA CTD PMID:27188386
(1->4)-beta-D-glucan (ISO) 17beta-estradiol (ISO) 2,3,7,8-tetrachlorodibenzodioxine (EXP,ISO) 2,3,7,8-Tetrachlorodibenzofuran (EXP) 2,4-dinitrotoluene (EXP) 2,6-dinitrotoluene (EXP) 2-hydroxypropanoic acid (ISO) 4,4'-sulfonyldiphenol (ISO) 4-octylphenol (ISO) 6-propyl-2-thiouracil (EXP) aflatoxin B1 (ISO) all-trans-retinoic acid (ISO) alpha-Zearalanol (EXP) amitrole (EXP) amphetamine (EXP) arsenite(3-) (ISO) arsenous acid (ISO) benzo[a]pyrene (ISO) benzo[a]pyrene diol epoxide I (ISO) benzo[e]pyrene (ISO) bis(2-ethylhexyl) phthalate (ISO) bisphenol A (EXP,ISO) bisphenol AF (ISO) bortezomib (ISO) butanal (ISO) cadmium atom (ISO) cadmium dichloride (ISO) caffeine (ISO) chlorpyrifos (ISO) cisplatin (ISO) cladribine (ISO) clozapine (ISO) cobalt atom (ISO) cobalt dichloride (ISO) copper(II) sulfate (ISO) coumarin (ISO) crotonaldehyde (ISO) Cuprizon (EXP) cytarabine (ISO) deoxynivalenol (ISO) diarsenic trioxide (ISO) diazinon (ISO) dibutyl phthalate (EXP) dicrotophos (ISO) diethylstilbestrol (ISO) dorsomorphin (ISO) doxorubicin (ISO) endosulfan (EXP) enzyme inhibitor (ISO) ethanol (ISO) etoposide (ISO) fenthion (ISO) formaldehyde (ISO) FR900359 (ISO) geldanamycin (ISO) genistein (ISO) gentamycin (EXP) glyphosate (EXP) haloperidol (ISO) hydroquinone (ISO) kaempferol (ISO) malathion (ISO) methapyrilene (ISO) methidathion (ISO) methimazole (EXP) methylmercury chloride (ISO) molibresib (ISO) morphine (EXP,ISO) N-acetyl-L-cysteine (ISO) nickel dichloride (EXP,ISO) Nonylphenol (ISO) ozone (ISO) p-chloromercuribenzoic acid (ISO) paracetamol (EXP,ISO) perfluorooctane-1-sulfonic acid (ISO) perfluorooctanoic acid (EXP) permethrin (ISO) phenylmercury acetate (ISO) pirinixic acid (ISO) potassium chloride (EXP) prednisolone (ISO) propiconazole (EXP) pyrvinium (ISO) quercetin (ISO) rac-lactic acid (ISO) SB 431542 (ISO) silicon dioxide (ISO) sodium arsenate (ISO) sodium arsenite (ISO) sulfadimethoxine (EXP) testosterone enanthate (ISO) thimerosal (ISO) thioacetamide (EXP) titanium dioxide (ISO) torcetrapib (ISO) trichostatin A (ISO) triphenyl phosphate (ISO) troglitazone (ISO) tungsten (ISO) valdecoxib (EXP) valproic acid (EXP,ISO) vinclozolin (EXP) vorinostat (ISO)
Biological Process
anterior/posterior pattern specification (IEA,ISO) cellular response to transforming growth factor beta stimulus (IMP) chromatin organization (IEA) circadian regulation of gene expression (IEA,ISO) cognition (IEA,ISO) definitive hemopoiesis (IEA,ISO) embryonic hemopoiesis (IEA,ISO) epigenetic regulation of gene expression (IEA,ISO) exploration behavior (IEA,ISO) fibroblast proliferation (IEA,ISO) homeostasis of number of cells within a tissue (IEA,ISO) membrane depolarization (IEP) methylation (IEA) negative regulation of DNA methylation-dependent heterochromatin formation (IEA,ISO) negative regulation of fibroblast proliferation (IEA,ISO) peptidyl-lysine monomethylation (ISO) positive regulation of DNA-templated transcription (IBA,IEA,ISO) positive regulation of gene expression (IMP) positive regulation of transcription by RNA polymerase II (IEA,ISO) post-embryonic development (IEA,ISO) protein modification process (IMP) protein-containing complex assembly (IEA,ISO) regulation of DNA-templated transcription (IEA) regulation of gene expression (IEA,ISO) regulation of short-term neuronal synaptic plasticity (IEA,ISO) response to light stimulus (IEA,ISO) response to potassium ion (IEP) spleen development (IEA,ISO) T-helper 2 cell differentiation (IEA,ISO) transcription initiation-coupled chromatin remodeling (IEA,ISO) visual learning (IEA,ISO)
Molecular Function
chromatin binding (IEA,ISO) DNA binding (IEA,ISO) DNA-binding transcription factor binding (IPI) histone H3K4 methyltransferase activity (IBA,IEA,ISO) histone H3K4 monomethyltransferase activity (IEA) histone H3K4 trimethyltransferase activity (IEA,ISO) identical protein binding (IEA,ISO) metal ion binding (IEA) methyltransferase activity (IEA) protein binding (ISO) protein homodimerization activity (IEA,ISO) protein-cysteine methyltransferase activity (IEA,ISO) transferase activity (IEA) unmethylated CpG binding (IEA,ISO) zinc ion binding (IEA,ISO)
1.
Histone methylase MLL1 has critical roles in tumor growth and angiogenesis and its knockdown suppresses tumor growth in vivo.
Ansari KI, etal., Oncogene. 2013 Jul 11;32(28):3359-70. doi: 10.1038/onc.2012.352. Epub 2012 Aug 27.
2.
Histone lysine methylation dynamics: establishment, regulation, and biological impact.
Black JC, etal., Mol Cell. 2012 Nov 30;48(4):491-507. doi: 10.1016/j.molcel.2012.11.006.
3.
Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.
Gaudet P, etal., Brief Bioinform. 2011 Sep;12(5):449-62. doi: 10.1093/bib/bbr042. Epub 2011 Aug 27.
4.
GATA3 (GATA-Binding Protein 3)/KMT2A (Lysine-Methyltransferase-2A) Complex by Increasing H3K4-3me (Trimethylated Lysine-4 of Histone-3) Upregulates NCX3 (Na+-Ca2+ Exchanger 3) Transcription and Contributes to Ischemic Preconditioning Neuroprotection.
Guida N, etal., Stroke. 2021 Nov;52(11):3680-3691. doi: 10.1161/STROKEAHA.121.034637. Epub 2021 Oct 25.
5.
Menin is necessary for long term maintenance of meningioma-1 driven leukemia.
Libbrecht C, etal., Leukemia. 2021 May;35(5):1405-1417. doi: 10.1038/s41375-021-01146-z. Epub 2021 Feb 4.
6.
ZF-CxxC domain-containing proteins, CpG islands and the chromatin connection.
Long HK, etal., Biochem Soc Trans. 2013 Jun;41(3):727-40. doi: 10.1042/BST20130028.
7.
OMIM Disease Annotation Pipeline
OMIM Disease Annotation Pipeline
8.
Epigenetic chromatin modifications in the cortical spreading depression.
Passaro D, etal., Brain Res. 2010 May 6;1329:1-9. doi: 10.1016/j.brainres.2010.03.001. Epub 2010 Mar 6.
9.
GOA pipeline
RGD automated data pipeline
10.
ClinVar Automated Import and Annotation Pipeline
RGD automated import pipeline for ClinVar variants, variant-to-disease annotations and gene-to-disease annotations
11.
Data Import for Chemical-Gene Interactions
RGD automated import pipeline for gene-chemical interactions
12.
Comprehensive gene review and curation
RGD comprehensive gene curation
13.
MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia.
Riedel SS, etal., J Clin Invest. 2016 Apr 1;126(4):1438-50. doi: 10.1172/JCI80825. Epub 2016 Feb 29.
14.
The COMPASS family of histone H3K4 methylases: mechanisms of regulation in development and disease pathogenesis.
Shilatifard A Annu Rev Biochem. 2012;81:65-95. doi: 10.1146/annurev-biochem-051710-134100.
15.
Inhibition of the H3K4 methyltransferase MLL1/WDR5 complex attenuates renal senescence in ischemia reperfusion mice by reduction of p16INK4a.
Shimoda H, etal., Kidney Int. 2019 Nov;96(5):1162-1175. doi: 10.1016/j.kint.2019.06.021. Epub 2019 Aug 1.
16.
Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations.
Thirman MJ, etal., N Engl J Med. 1993 Sep 23;329(13):909-14.
17.
Deregulated expression of selected histone methylases and demethylases in prostate carcinoma.
Vieira FQ, etal., Endocr Relat Cancer. 2013 Dec 16;21(1):51-61. doi: 10.1530/ERC-13-0375. Print 2014 Feb.
18.
Clinical features and next-generation sequencing landscape of essential thrombocythemia, prefibrotic primary myelofibrosis, and overt fibrotic primary myelofibrosis: a Chinese monocentric retrospective study.
Zhang L, etal., J Cancer Res Clin Oncol. 2022 Jun 22. doi: 10.1007/s00432-022-04067-1.
Kmt2a Rat Assembly Chr Position (strand) Source Genome Browsers JBrowse NCBI UCSC Ensembl GRCr8 8 54,013,547 - 54,089,219 (-) NCBI GRCr8 mRatBN7.2 8 45,116,763 - 45,193,320 (-) NCBI mRatBN7.2 mRatBN7.2 mRatBN7.2 Ensembl 8 45,118,814 - 45,193,181 (-) Ensembl mRatBN7.2 Ensembl Rnor_6.0 8 49,110,407 - 49,185,872 (-) NCBI Rnor6.0 Rnor_6.0 rn6 Rnor6.0 Rnor_6.0 Ensembl 8 49,114,990 - 49,158,971 (-) Ensembl Rnor6.0 rn6 Rnor6.0 Rnor_5.0 8 47,728,915 - 47,804,551 (-) NCBI Rnor5.0 Rnor_5.0 rn5 Rnor5.0 RGSC_v3.4 8 47,759,175 - 47,834,586 (-) NCBI RGSC3.4 RGSC_v3.4 rn4 RGSC3.4 Celera 8 44,701,780 - 44,782,476 (-) NCBI Celera Cytogenetic Map 8 q22 NCBI
KMT2A Human Assembly Chr Position (strand) Source Genome Browsers JBrowse NCBI UCSC Ensembl GRCh38 11 118,436,492 - 118,526,832 (+) NCBI GRCh38 GRCh38 hg38 GRCh38 GRCh38.p14 Ensembl 11 118,436,456 - 118,526,832 (+) Ensembl GRCh38 hg38 GRCh38 GRCh37 11 118,307,207 - 118,397,547 (+) NCBI GRCh37 GRCh37 hg19 GRCh37 Build 36 11 117,812,415 - 117,901,146 (+) NCBI NCBI36 Build 36 hg18 NCBI36 Build 34 11 117,812,414 - 117,901,146 NCBI Celera 11 115,467,997 - 115,556,730 (+) NCBI Celera Cytogenetic Map 11 q23.3 NCBI HuRef 11 114,244,065 - 114,334,229 (+) NCBI HuRef CHM1_1 11 118,193,852 - 118,284,190 (+) NCBI CHM1_1 T2T-CHM13v2.0 11 118,455,794 - 118,546,121 (+) NCBI T2T-CHM13v2.0
Kmt2a Mouse Assembly Chr Position (strand) Source Genome Browsers JBrowse NCBI UCSC Ensembl GRCm39 9 44,714,652 - 44,793,492 (-) NCBI GRCm39 GRCm39 mm39 GRCm39 Ensembl 9 44,714,652 - 44,792,594 (-) Ensembl GRCm39 Ensembl GRCm38 9 44,803,355 - 44,881,352 (-) NCBI GRCm38 GRCm38 mm10 GRCm38 GRCm38.p6 Ensembl 9 44,803,355 - 44,881,296 (-) Ensembl GRCm38 mm10 GRCm38 MGSCv37 9 44,611,438 - 44,689,357 (-) NCBI GRCm37 MGSCv37 mm9 NCBIm37 MGSCv36 9 44,554,350 - 44,632,269 (-) NCBI MGSCv36 mm8 Celera 9 42,068,287 - 42,146,334 (-) NCBI Celera Cytogenetic Map 9 A5.2 NCBI cM Map 9 24.84 NCBI
Kmt2a Chinchilla Assembly Chr Position (strand) Source Genome Browsers JBrowse NCBI UCSC Ensembl ChiLan1.0 Ensembl NW_004955412 19,586,141 - 19,665,527 (+) Ensembl ChiLan1.0 ChiLan1.0 NW_004955412 19,586,435 - 19,670,149 (+) NCBI ChiLan1.0 ChiLan1.0
KMT2A Bonobo Assembly Chr Position (strand) Source Genome Browsers JBrowse NCBI UCSC Ensembl NHGRI_mPanPan1-v2 9 119,139,884 - 119,230,967 (+) NCBI NHGRI_mPanPan1-v2 NHGRI_mPanPan1 11 120,244,773 - 120,335,992 (+) NCBI NHGRI_mPanPan1 Mhudiblu_PPA_v0 11 113,273,198 - 113,364,404 (+) NCBI Mhudiblu_PPA_v0 Mhudiblu_PPA_v0 panPan3 PanPan1.1 11 117,203,337 - 117,294,755 (+) NCBI panpan1.1 PanPan1.1 panPan2 PanPan1.1 Ensembl 11 117,204,820 - 117,290,100 (+) Ensembl panpan1.1 panPan2
KMT2A Dog Assembly Chr Position (strand) Source Genome Browsers JBrowse NCBI UCSC Ensembl CanFam3.1 5 15,212,559 - 15,302,825 (-) NCBI CanFam3.1 CanFam3.1 canFam3 CanFam3.1 CanFam3.1 Ensembl 5 15,217,348 - 15,270,971 (-) Ensembl CanFam3.1 canFam3 CanFam3.1 Dog10K_Boxer_Tasha 5 15,263,739 - 15,351,690 (-) NCBI Dog10K_Boxer_Tasha ROS_Cfam_1.0 5 15,154,723 - 15,242,720 (-) NCBI ROS_Cfam_1.0 ROS_Cfam_1.0 Ensembl 5 15,155,965 - 15,242,720 (-) Ensembl ROS_Cfam_1.0 Ensembl UMICH_Zoey_3.1 5 15,293,171 - 15,381,085 (-) NCBI UMICH_Zoey_3.1 UNSW_CanFamBas_1.0 5 15,196,657 - 15,284,731 (-) NCBI UNSW_CanFamBas_1.0 UU_Cfam_GSD_1.0 5 15,237,660 - 15,325,572 (-) NCBI UU_Cfam_GSD_1.0
Kmt2a Squirrel Assembly Chr Position (strand) Source Genome Browsers JBrowse NCBI UCSC Ensembl HiC_Itri_2 NW_024404947 100,558,662 - 100,644,258 (+) NCBI HiC_Itri_2 SpeTri2.0 Ensembl NW_004936542 3,391,774 - 3,562,147 (+) Ensembl SpeTri2.0 SpeTri2.0 Ensembl SpeTri2.0 NW_004936542 3,480,071 - 3,566,823 (+) NCBI SpeTri2.0 SpeTri2.0 SpeTri2.0
KMT2A Pig Assembly Chr Position (strand) Source Genome Browsers JBrowse NCBI UCSC Ensembl Sscrofa11.1 Ensembl 9 45,743,397 - 45,824,884 (+) Ensembl Sscrofa11.1 susScr11 Sscrofa11.1 Sscrofa11.1 9 45,743,566 - 45,828,559 (+) NCBI Sscrofa11.1 Sscrofa11.1 susScr11 Sscrofa11.1 Sscrofa10.2 9 50,878,276 - 50,914,778 (-) NCBI Sscrofa10.2 Sscrofa10.2 susScr3
KMT2A Green Monkey Assembly Chr Position (strand) Source Genome Browsers JBrowse NCBI UCSC Ensembl ChlSab1.1 1 109,819,748 - 109,912,763 (+) NCBI ChlSab1.1 ChlSab1.1 chlSab2 ChlSab1.1 Ensembl 1 109,853,758 - 109,908,113 (+) Ensembl ChlSab1.1 ChlSab1.1 Ensembl chlSab2 Vero_WHO_p1.0 NW_023666043 16,125,381 - 16,218,277 (-) NCBI Vero_WHO_p1.0 Vero_WHO_p1.0
Kmt2a
.
Predicted Target Of
Count of predictions: 84 Count of miRNA genes: 73 Interacting mature miRNAs: 75 Transcripts: ENSRNOT00000020573 Prediction methods: Microtar, Miranda, Rnahybrid, Targetscan Result types: miRGate_prediction
1298065 Scl16 Serum cholesterol level QTL 16 3.8 blood cholesterol amount (VT:0000180) plasma total cholesterol level (CMO:0000585) 8 30856404 75856404 Rat 1554321 Bmd3 Bone mineral density QTL 3 7.9 0.0001 femur mineral mass (VT:0010011) volumetric bone mineral density (CMO:0001553) 8 40952565 123900184 Rat 1578769 Uae31 Urinary albumin excretion QTL 31 3.3 0.001 urine albumin amount (VT:0002871) urine albumin excretion rate (CMO:0000757) 8 30848154 101699754 Rat 1298079 Activ2 Activity QTL 2 9.5 0.000001 voluntary movement trait (VT:0003491) rearing measurement (CMO:0001515) 8 41866876 86866876 Rat 11556286 Cm81 Cardiac mass QTL 81 0.01 heart mass (VT:0007028) heart weight to body weight ratio (CMO:0000074) 8 30848154 61290444 Rat 70161 Bp62 Blood pressure QTL 62 2.9 0.001 arterial blood pressure trait (VT:2000000) systolic blood pressure (CMO:0000004) 8 42692684 90165460 Rat 1578765 Klgr1 Kidney lesion grade QTL 1 3.3 0.0001 kidney morphology trait (VT:0002135) organ lesion measurement (CMO:0000677) 8 30848154 101699754 Rat 1582222 Epfw2 Epididymal fat weight QTL 2 3.2 0.0005 epididymal fat pad mass (VT:0010421) epididymal fat pad weight to body weight ratio (CMO:0000658) 8 31737729 76737729 Rat 1354627 Despr14 Despair related QTL 14 0.0056 locomotor behavior trait (VT:0001392) amount of experiment time spent in a discrete space in an experimental apparatus (CMO:0000958) 8 7688955 52688955 Rat 61464 Niddm11 Non-insulin dependent diabetes mellitus QTL 11 3.1 0.001 blood insulin amount (VT:0001560) plasma insulin level (CMO:0000342) 8 35582032 80582032 Rat 1578755 Pur5 Proteinuria QTL 5 3.3 0.0001 urine total protein amount (VT:0000032) urine total protein excretion rate (CMO:0000756) 8 30848154 101699754 Rat 1300146 Rf17 Renal function QTL 17 2.9 renal blood flow trait (VT:2000006) absolute change in renal blood flow rate (CMO:0001168) 8 28242912 73242912 Rat 8662823 Vetf5 Vascular elastic tissue fragility QTL 5 1.9 artery integrity trait (VT:0010639) patent ductus arteriosus score (CMO:0002566) 8 28242912 99525068 Rat 2313088 Bss75 Bone structure and strength QTL 75 3.1 0.0001 body length (VT:0001256) body length, nose to rump (CMO:0000079) 8 30848154 82460899 Rat 1358896 Bp262 Blood pressure QTL 262 2.89 arterial blood pressure trait (VT:2000000) mean arterial blood pressure (CMO:0000009) 8 27205715 99103503 Rat 731182 Uae24 Urinary albumin excretion QTL 24 6.4 urine albumin amount (VT:0002871) urine albumin excretion rate (CMO:0000757) 8 19331152 93965294 Rat 724514 Uae15 Urinary albumin excretion QTL 15 2.9 urine albumin amount (VT:0002871) urine albumin excretion rate (CMO:0000757) 8 29502665 70386295 Rat 61353 Bp35 Blood pressure QTL 35 0.001 arterial blood pressure trait (VT:2000000) diastolic blood pressure (CMO:0000005) 8 30848154 61290444 Rat 631842 Inf1 Infertility severity QTL 1 4.1 0.001 seminal gland mass (VT:0010524) seminal vesicle wet weight (CMO:0001603) 8 22662330 67662330 Rat 737824 Hcar10 Hepatocarcinoma resistance QTL 10 2.9 liver integrity trait (VT:0010547) liver tumorous lesion number (CMO:0001068) 8 40713066 82925667 Rat 1359033 Bp273 Blood pressure QTL 273 arterial blood pressure trait (VT:2000000) systolic blood pressure (CMO:0000004) 8 30848154 61290444 Rat 1331769 Rf39 Renal function QTL 39 3.871 urine output (VT:0003620) timed urine volume (CMO:0000260) 8 41866876 75097878 Rat 61358 Bp39 Blood pressure QTL 39 2 arterial blood pressure trait (VT:2000000) systolic blood pressure (CMO:0000004) 8 35551938 80551938 Rat 1358906 Bp253 Blood pressure QTL 253 4 0.0004 arterial blood pressure trait (VT:2000000) mean arterial blood pressure (CMO:0000009) 8 40713066 93965294 Rat 1358907 Cm40 Cardiac mass QTL 40 1.89 heart mass (VT:0007028) heart weight to body weight ratio (CMO:0000074) 8 27205715 99103503 Rat 1331744 Bp217 Blood pressure QTL 217 3.398 arterial blood pressure trait (VT:2000000) systolic blood pressure (CMO:0000004) 8 30848154 58482492 Rat 2316950 Scl66 Serum cholesterol level QTL 66 4.1 blood cholesterol amount (VT:0000180) plasma total cholesterol level (CMO:0000585) 8 30848259 105647037 Rat 1358892 Kidm26 Kidney mass QTL 26 3.69 kidney mass (VT:0002707) both kidneys wet weight to body weight ratio (CMO:0000340) 8 27205715 99103503 Rat 1359021 Bp271 Blood pressure QTL 271 1.8 arterial blood pressure trait (VT:2000000) mean arterial blood pressure (CMO:0000009) 8 26644912 46711092 Rat 631216 Stl9 Serum triglyceride level QTL 9 4.71 0.0001 blood triglyceride amount (VT:0002644) serum triglyceride level (CMO:0000360) 8 41867010 70386132 Rat 61373 Mcs4 Mammary carcinoma susceptibility QTL 4 1.1 mammary gland integrity trait (VT:0010552) mammary tumor number (CMO:0000343) 8 16290444 61290444 Rat 2313057 Bss76 Bone structure and strength QTL 76 3 0.0001 tibia size trait (VT:0100001) tibia midshaft cross-sectional area (CMO:0001717) 8 30848154 82460899 Rat 12879878 Bw183 Body weight QTL 183 0.001 body mass (VT:0001259) body weight (CMO:0000012) 8 43296169 98968765 Rat 1549908 Neudeg1 Neurodegradation QTL 1 5.5 0 nervous system integrity trait (VT:0010566) logarithm of the ratio of the lesioned side motor neuron count to contralateral side motor neuron count (CMO:0001986) 8 30188867 94457446 Rat 12879879 Cm99 Cardiac mass QTL 99 0.001 heart mass (VT:0007028) heart weight to body weight ratio (CMO:0000074) 8 43296169 98968765 Rat 2317030 Wbc5 White blood cell count QTL 5 3.21 0.005 leukocyte quantity (VT:0000217) white blood cell count (CMO:0000027) 8 8736635 53736635 Rat 1331804 Cm30 Cardiac mass QTL 30 3.77443 heart mass (VT:0007028) heart wet weight (CMO:0000069) 8 28242912 53961020 Rat 2313067 Bss77 Bone structure and strength QTL 77 3.1 0.0001 tibia size trait (VT:0100001) tibia midshaft endosteal cross-sectional area (CMO:0001716) 8 30848154 82460899 Rat 2317032 Ginf2 Gastrointestinal inflammation QTL 2 3.21 0.005 liver integrity trait (VT:0010547) liver granuloma severity score (CMO:0002157) 8 4705810 49705810 Rat 2301416 Bp315 Blood pressure QTL 315 0.008 arterial blood pressure trait (VT:2000000) mean arterial blood pressure (CMO:0000009) 8 7670578 52670578 Rat 12879880 Cm100 Cardiac mass QTL 100 0.001 heart left ventricle mass (VT:0007031) heart left ventricle weight to body weight ratio (CMO:0000530) 8 43296169 98968765 Rat 12879881 Cm101 Cardiac mass QTL 101 0.001 heart right ventricle mass (VT:0007033) heart right ventricle weight to body weight ratio (CMO:0000914) 8 43296169 98968765 Rat 12879882 Am8 Aortic mass QTL 8 0.001 aorta mass (VT:0002845) aorta weight to aorta length to body weight ratio (CMO:0002722) 8 43296169 98968765 Rat 2317036 Livw3 Liver weight QTL 3 2.43 0.01 liver mass (VT:0003402) liver weight to body weight ratio (CMO:0000633) 8 4705810 49705810 Rat 12879883 Kidm65 Kidney mass QTL 65 0.001 kidney mass (VT:0002707) both kidneys wet weight to body weight ratio (CMO:0000340) 8 43296169 98968765 Rat 12880023 Bw184 Body weight QTL 184 0.001 body mass (VT:0001259) body weight (CMO:0000012) 8 2097640 47097640 Rat 5684993 Bmd84 Bone mineral density QTL 84 4.1 tibia mineral mass (VT:1000283) bone mineral content (CMO:0001554) 8 42692684 50095447 Rat 12880028 Cm103 Cardiac mass QTL 103 0.02 heart left ventricle mass (VT:0007031) heart left ventricle weight to body weight ratio (CMO:0000530) 8 2097640 47097640 Rat 2317051 Aia18 Adjuvant induced arthritis QTL 18 2.42 joint integrity trait (VT:0010548) left rear ankle joint diameter (CMO:0002149) 8 8736635 53736635 Rat 2317048 Ginf1 Gastrointestinal inflammation QTL 1 3.52 0.005 cecum mucosa thickness (VT:0010234) enterocolitis severity score (CMO:0002138) 8 4705810 49705810 Rat 12880025 Cm102 Cardiac mass QTL 102 0.044 heart mass (VT:0007028) heart wet weight to body weight ratio (CMO:0002408) 8 2097640 47097640 Rat 1558646 Swd5 Spike wave discharge measurement QTL 5 3.45 0.00036 brain electrophysiology trait (VT:0010557) brain spike-and-wave discharge frequency (CMO:0001742) 8 14906751 59906751 Rat 2302278 Gluco36 Glucose level QTL 36 4.2 blood glucose amount (VT:0000188) blood glucose level (CMO:0000046) 8 29502665 50095447 Rat 12880044 Am9 Aortic mass QTL 9 0.007 aorta mass (VT:0002845) aorta weight to aorta length to body weight ratio (CMO:0002722) 8 2097640 47097640 Rat 631648 Stl5 Serum triglyceride level QTL 5 4 0.0003 blood triglyceride amount (VT:0002644) plasma triglyceride level (CMO:0000548) 8 27205715 54998217 Rat 1331838 Niddm61 Non-insulin dependent diabetes mellitus QTL 61 3.53 0.0004 blood insulin amount (VT:0001560) plasma insulin level (CMO:0000342) 8 36469535 99083736 Rat 631650 Stl6 Serum triglyceride level QTL 6 4 0.0019 blood triglyceride amount (VT:0002644) plasma triglyceride level (CMO:0000548) 8 10378157 112202585 Rat 1581557 Eae16 Experimental allergic encephalomyelitis QTL 16 3.8 nervous system integrity trait (VT:0010566) experimental autoimmune encephalomyelitis incidence/prevalence measurement (CMO:0001046) 8 8462195 110921472 Rat 631271 Lecl1 Lens clarity QTL 1 0.001 lens clarity trait (VT:0001304) age of onset/diagnosis of cataract (CMO:0001584) 8 18984168 84531599 Rat 2303564 Gluco43 Glucose level QTL 43 3 blood glucose amount (VT:0000188) blood glucose level (CMO:0000046) 8 26130187 71130187 Rat 1598824 Memor4 Memory QTL 4 2.5 exploratory behavior trait (VT:0010471) total horizontal distance resulting from voluntary locomotion in an experimental apparatus (CMO:0001443) 8 9712220 53356647 Rat 2313046 Bss78 Bone structure and strength QTL 78 3.5 0.0001 tibia strength trait (VT:1000284) tibia total energy absorbed before break (CMO:0001736) 8 30848154 82460899 Rat 1354595 Despr4 Despair related QTL 4 2.16 0.0036 locomotor behavior trait (VT:0001392) amount of time spent in voluntary immobility (CMO:0001043) 8 7688955 52688955 Rat 2303572 Insul13 Insulin level QTL 13 2 blood insulin amount (VT:0001560) blood insulin level (CMO:0000349) 8 26130187 71130187 Rat
BF397432
Rat Assembly Chr Position (strand) Source JBrowse mRatBN7.2 8 45,168,205 - 45,168,345 (+) MAPPER mRatBN7.2 Rnor_6.0 8 49,161,843 - 49,161,982 NCBI Rnor6.0 Rnor_5.0 8 47,780,305 - 47,780,444 UniSTS Rnor5.0 RGSC_v3.4 8 47,810,648 - 47,810,787 UniSTS RGSC3.4 Celera 8 44,753,197 - 44,753,336 UniSTS RH 3.4 Map 8 450.6 UniSTS Cytogenetic Map 8 q22 UniSTS
Mll1
Rat Assembly Chr Position (strand) Source JBrowse GRCr8 8 54,051,330 - 54,052,138 (+) Marker Load Pipeline mRatBN7.2 8 45,154,547 - 45,155,354 (+) MAPPER mRatBN7.2 Rnor_6.0 8 49,148,185 - 49,148,991 NCBI Rnor6.0 Rnor_5.0 8 47,766,647 - 47,767,453 UniSTS Rnor5.0 RGSC_v3.4 8 47,796,990 - 47,797,796 UniSTS RGSC3.4 Celera 8 44,739,562 - 44,740,368 UniSTS Cytogenetic Map 8 q22 UniSTS
Click on a value in the shaded box below the category label to view a detailed expression data table for that system.
alimentary part of gastrointestinal system
9
11
49
113
91
90
59
25
59
6
218
97
93
45
60
31
Too many to show, limit is 500. Download them if you would like to view them all.
Ensembl Acc Id:
ENSRNOT00000020573 ⟹ ENSRNOP00000020573
Type:
CODING
Position:
Rat Assembly Chr Position (strand) Source mRatBN7.2 Ensembl 8 45,118,814 - 45,193,181 (-) Ensembl Rnor_6.0 Ensembl 8 49,114,990 - 49,158,971 (-) Ensembl
RefSeq Acc Id:
NM_001108139 ⟹ NP_001101609
RefSeq Status:
VALIDATED
Type:
CODING
Position:
Rat Assembly Chr Position (strand) Source GRCr8 8 54,013,547 - 54,089,219 (-) NCBI mRatBN7.2 8 45,116,763 - 45,192,437 (-) NCBI
RefSeq Acc Id:
NM_001419940 ⟹ NP_001406869
RefSeq Status:
VALIDATED
Type:
CODING
Position:
Rat Assembly Chr Position (strand) Source GRCr8 8 54,013,547 - 54,089,219 (-) NCBI mRatBN7.2 8 45,116,763 - 45,192,437 (-) NCBI
RefSeq Acc Id:
XM_039082345 ⟹ XP_038938273
Type:
CODING
Position:
Rat Assembly Chr Position (strand) Source GRCr8 8 54,013,555 - 54,089,191 (-) NCBI mRatBN7.2 8 45,116,771 - 45,193,319 (-) NCBI
RefSeq Acc Id:
XM_039082346 ⟹ XP_038938274
Type:
CODING
Position:
Rat Assembly Chr Position (strand) Source GRCr8 8 54,013,555 - 54,089,191 (-) NCBI mRatBN7.2 8 45,116,771 - 45,193,320 (-) NCBI
RefSeq Acc Id:
XM_039082347 ⟹ XP_038938275
Type:
CODING
Position:
Rat Assembly Chr Position (strand) Source GRCr8 8 54,013,555 - 54,089,191 (-) NCBI mRatBN7.2 8 45,116,771 - 45,193,320 (-) NCBI
RefSeq Acc Id:
XM_039082348 ⟹ XP_038938276
Type:
CODING
Position:
Rat Assembly Chr Position (strand) Source GRCr8 8 54,013,555 - 54,089,191 (-) NCBI mRatBN7.2 8 45,116,771 - 45,193,319 (-) NCBI
RefSeq Acc Id:
XM_063265434 ⟹ XP_063121504
Type:
CODING
Position:
Rat Assembly Chr Position (strand) Source GRCr8 8 54,013,555 - 54,089,191 (-) NCBI
RefSeq Acc Id:
XM_063265435 ⟹ XP_063121505
Type:
CODING
Position:
Rat Assembly Chr Position (strand) Source GRCr8 8 54,013,555 - 54,089,191 (-) NCBI
RefSeq Acc Id:
XM_063265436 ⟹ XP_063121506
Type:
CODING
Position:
Rat Assembly Chr Position (strand) Source GRCr8 8 54,013,555 - 54,057,874 (-) NCBI
RefSeq Acc Id:
XM_063265437 ⟹ XP_063121507
Type:
CODING
Position:
Rat Assembly Chr Position (strand) Source GRCr8 8 54,013,555 - 54,089,191 (-) NCBI
Ensembl Acc Id:
ENSRNOP00000020573 ⟸ ENSRNOT00000020573
RefSeq Acc Id:
XP_038938275 ⟸ XM_039082347
- Peptide Label:
isoform X3
- UniProtKB:
A6J416 (UniProtKB/TrEMBL)
RefSeq Acc Id:
XP_038938274 ⟸ XM_039082346
- Peptide Label:
isoform X2
- UniProtKB:
A6J416 (UniProtKB/TrEMBL)
RefSeq Acc Id:
XP_038938276 ⟸ XM_039082348
- Peptide Label:
isoform X6
- UniProtKB:
A6J416 (UniProtKB/TrEMBL)
RefSeq Acc Id:
XP_038938273 ⟸ XM_039082345
- Peptide Label:
isoform X1
- UniProtKB:
F1M0L3 (UniProtKB/TrEMBL), A6J416 (UniProtKB/TrEMBL)
RefSeq Acc Id:
NP_001406869 ⟸ NM_001419940
- Peptide Label:
isoform 2
- UniProtKB:
A6J416 (UniProtKB/TrEMBL)
RefSeq Acc Id:
NP_001101609 ⟸ NM_001108139
- Peptide Label:
isoform 1
- UniProtKB:
A6J416 (UniProtKB/TrEMBL)
RefSeq Acc Id:
XP_063121505 ⟸ XM_063265435
- Peptide Label:
isoform X5
- UniProtKB:
A6J416 (UniProtKB/TrEMBL)
RefSeq Acc Id:
XP_063121504 ⟸ XM_063265434
- Peptide Label:
isoform X4
- UniProtKB:
A6J416 (UniProtKB/TrEMBL)
RefSeq Acc Id:
XP_063121507 ⟸ XM_063265437
- Peptide Label:
isoform X8
- UniProtKB:
A6J416 (UniProtKB/TrEMBL)
RefSeq Acc Id:
XP_063121506 ⟸ XM_063265436
- Peptide Label:
isoform X7
- UniProtKB:
A6J416 (UniProtKB/TrEMBL)
Date
Current Symbol
Current Name
Previous Symbol
Previous Name
Description
Reference
Status
2016-02-17
Kmt2a
lysine methyltransferase 2A
Kmt2a
lysine (K)-specific methyltransferase 2A
Nomenclature updated to reflect human and mouse nomenclature
1299863 APPROVED
2013-05-15
Kmt2a
lysine (K)-specific methyltransferase 2A
Mll
myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila)
Nomenclature updated to reflect human and mouse nomenclature
1299863 APPROVED
2013-02-27
Mll
myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila)
Mll1
myeloid/lymphoid or mixed-lineage leukemia 1
Nomenclature updated to reflect human and mouse nomenclature
1299863 APPROVED
2008-03-06
Mll1
myeloid/lymphoid or mixed-lineage leukemia 1
Mll
myeloid/lymphoid or mixed-lineage leukemia
Nomenclature updated to reflect human and mouse nomenclature
1299863 APPROVED
2007-04-13
myeloid/lymphoid or mixed-lineage leukemia
Mll
myeloid/lymphoid or mixed-lineage leukemia (mapped)
Name updated
737654 APPROVED
2007-04-11
Mll
myeloid/lymphoid or mixed-lineage leukemia (mapped)
Mll_mapped
myeloid/lymphoid or mixed-lineage leukemia (mapped)
Data merged from RGD:3093
737654 APPROVED
2006-11-19
Mll
myeloid/lymphoid or mixed-lineage leukemia (mapped)
Symbol and Name status set to provisional
70820 PROVISIONAL
2005-11-17
Mll_mapped
myeloid/lymphoid or mixed-lineage leukemia (mapped)
Symbol and Name updated
1556543 APPROVED
2002-06-10
Mll
Mixed-lineage leukemia (also acute lymphocytic leukemia 1 or tritorax Drosophila gene)
Symbol and Name status set to approved
70586 APPROVED
